Dengue Virus (DENV) Antigens & Antibodies

Research-grade reagents for Dengue virus (DENV) research — investigating serotype-specific neutralization, antibody-dependent enhancement (ADE), and NS1-based antigen detection across all four Dengue serotypes (DENV-1/2/3/4). Our portfolio includes domain-mapped recombinant antibodies targeting E protein (DI/DII/DIII), InVivoMAb functional-grade clones for in vivo neutralization and ADE studies, serotype-specific NS1 detection antibodies, and His-tagged recombinant antigens for immunization and assay development. The Envelope (E) protein mediates viral attachment and membrane fusion through domain-dependent receptor binding; the non-structural protein NS1 is expressed on infected cell surfaces and serves as a diagnostic marker; InVivoMAb clones with validated neutralization activity enable mechanistic studies of serotype-specific protection and cross-reactive antibody responses. Flavivirus cross-reactivity reagents support investigation of Dengue-Zika interactions and pan-flavivirus serological screening essential for vaccine development and diagnostic assay optimization. RUO

Why Researchers Choose abinScience

Serotype-Specific E Protein Reagents Individual Envelope protein antibodies and recombinant antigens for DENV-1, DENV-2, DENV-3, and DENV-4. Domain-mapped clones (DI, DII, DIII/EDIII) enable serotype-discrimination binding studies, neutralization assays, and structural epitope mapping for vaccine antigen design.

NS1 Detection Antibodies & Antigens Recombinant and polyclonal anti-NS1 antibodies validated for ELISA, Western blot, and immunohistochemistry. Serotype-specific NS1 recombinant proteins (His-tagged) available for all four serotypes as coating antigens, positive controls, and diagnostic assay standards for early-phase infection detection.

InVivoMAb Functional-Grade & Cross-Reactive Clones Low-endotoxin, azide-free antibodies for in vivo neutralization, antibody-dependent enhancement (ADE), and passive immunization studies. Anti-E/EDIII and anti-prM clones with validated neutralization activity; pan-serotype anti-E/DII-FL clone (1C19) covering DENV-1/2/3/4. Cross-reactive DENV/ZIKV clones for flavivirus interaction research.

All products manufactured by AtaGenix Laboratories under ISO 9001 & ISO 13485 quality systems.

References

1. Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504-507. DOI

2. Screaton G, Mongkolsapaya J, Yacoub S, Roberts C. New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol. 2015;15(12):745-759. DOI

3. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Nat Rev Immunol. 2013;13(10):733-745. DOI

4. Halstead SB. Dengue antibody-dependent enhancement: knowns and unknowns. Microbiol Spectr. 2014;2(6):AID-0022-2014. DOI